Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol

被引:110
作者
deGoma, Emil M. [1 ]
Leeper, Nicholas J. [1 ]
Heidenreich, Paul A. [1 ,2 ]
机构
[1] Stanford Univ Hosp, Falk Cardiovasc Res Ctr, Dept Cardiol, Stanford, CA 94305 USA
[2] Vet Adm Palo Alto Hlth Care Syst, Dept Cardiol, Palo Alto, CA USA
关键词
D O I
10.1016/j.jacc.2007.07.086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We sought to evaluate the significance of high-density lipoprotein cholesterol (HDL-C) in the context of low low-density lipoprotein cholesterol (LDL-C). Background Earlier studies support an inverse correlation between circulating HDL-C and coronary risk in patients with normal or elevated LDL-C. Methods This study involved 4,188 patients attending the Palo Alto Veterans Administration Medical Center or affiliated clinics with LDL-C levels below 60 mg/dl. Outcomes were examined 1 year after the index LDL-C date. The combined primary end point was myocardial injury or hospitalization from ischemic heart disease. The secondary end point was all-cause mortality. Results Mean HDL-C levels (mg/dl) by quartile (Q) were: Q1 28 mg,/dl, Q2 36 mg/dl, Q3 43 mg/dl, and Q4 63 mg/dl. The rate of myocardial injury or hospitalization for ischemic heart disease showed an inverse relationship to HDL-C (adjusted odds ratios: Q1 1.59 [95% confidence interval (CI) 1.16 to 2.19], Q2 1.39 [95% CI 1.01 to 1.92], Q3 1.33 [95% CI 0.96 to 1.84], and Q4 reference) that persisted regardless of statin use or recent myocardial injury. Analyzing HDL-C as a continuous variable revealed a 10% [95% CI 3% to 17%] increase in the combined end point of myocardial injury or hospitalization for ischemic heart disease for every 10-mg/dl decrease in HDL-C. The unadjusted and adjusted incidence of all-cause mortality demonstrated a U-shaped relationship to HDL-C (adjusted odds ratios: Q1 1.13 [95% CI 0.79 to 1.62], Q2 0.97 [95% CI 0.67 to 1.40], Q3 0.74 [95% CI 0.50 to 1.09], and Q4 reference). Conclusions The inverse relationship between HDL-C and coronary risk persists even among patients with LDL-C below 60 mg/dl, although a U-shaped relationship is observed between HDL-C and all-cause mortality.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 32 条
[21]  
Perova Natalia V., 1995, Annals of Epidemiology, V5, P179, DOI 10.1016/1047-2797(94)00104-2
[22]   Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial [J].
Robins, SJ ;
Collins, D ;
Wittes, JT ;
Papademetriou, V ;
Deedwania, PC ;
Schaefer, EJ ;
McNamara, JR ;
Kashyap, ML ;
Hershman, JM ;
Wexler, LF ;
Rubins, HB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12) :1585-1591
[23]   DISTRIBUTION OF LIPIDS IN 8,500 MEN WITH CORONARY-ARTERY DISEASE [J].
RUBINS, HB ;
ROBINS, SJ ;
COLLINS, D ;
IRANMANESH, A ;
WILT, TJ ;
MANN, D ;
MAYOSMITH, M ;
FAAS, FH ;
ELAM, MB ;
RUTAN, GH ;
ANDERSON, JW ;
KASHYAP, ML ;
SCHECTMAN, G .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 75 (17) :1196-1201
[24]   Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].
Rubins, HB ;
Robins, SJ ;
Collins, D ;
Fye, CL ;
Anderson, JW ;
Elam, MB ;
Faas, FH ;
Linares, E ;
Schaefer, EJ ;
Schectman, G ;
Wilt, TJ ;
Wittes, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418
[25]   Coronary heart disease in patients with low LDL-cholesterol - Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors [J].
Sacks, FM ;
Tonkin, AM ;
Craven, T ;
Pfeffer, MA ;
Shepherd, J ;
Keech, A ;
Furberg, CD ;
Braunwald, E .
CIRCULATION, 2002, 105 (12) :1424-1428
[26]   HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND CORONARY, CARDIOVASCULAR AND ALL CAUSE MORTALITY AMONG MIDDLE-AGED NORWEGIAN MEN AND WOMEN [J].
STENSVOLD, I ;
URDAL, P ;
THURMER, H ;
TVERDAL, A ;
LUNDLARSEN, PG ;
FOSS, OP .
EUROPEAN HEART JOURNAL, 1992, 13 (09) :1155-1163
[27]  
Szeto HC, 2002, AM J MANAG CARE, V8, P37
[28]   Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [J].
Taylor, AJ ;
Sullenberger, LE ;
Lee, HJ ;
Lee, JK ;
Grace, KA .
CIRCULATION, 2004, 110 (23) :3512-3517
[29]   The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 [J].
Taylor, Allen J. ;
Lee, Hyun J. ;
Sullenberger, Lance E. .
CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (11) :2243-2250
[30]   Heart disease and stroke statistics - 2006 update - A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee [J].
Thom, T ;
Haase, N ;
Rosamond, W ;
Howard, VJ ;
Rumsfeld, J ;
Manolio, T ;
Zheng, ZJ ;
Flegal, K ;
O'Donnell, C ;
Kittner, S ;
Lloyd-Jones, D ;
Goff, DC ;
Hong, YL ;
Adams, R ;
Friday, G ;
Furie, K ;
Gorelick, P ;
Kissela, B ;
Marler, J ;
Meigs, J ;
Roger, V ;
Sidney, S ;
Sorlie, P ;
Steinberger, J ;
Wasserthiel-Smoller, S ;
Wilson, M ;
Wolf, P .
CIRCULATION, 2006, 113 (06) :E85-E151